Systematic reviews have played a key role in assessing the effects of treatments for women with breast cancer. In a new Cochrane Review in April 2012, Lorenzo Moja from the Department of Public Health at the University of Milan in Italy and colleagues have examined the benefits and harms of the drug Trastuzumab.